Intelligent Photosensitive Mesenchymal Stem Cells and Cell-Derived Microvesicles for Photothermal Therapy of Prostate Cancer
- PMID: 30662822
- PMCID: PMC6328305
- DOI: 10.7150/ntno.28450
Intelligent Photosensitive Mesenchymal Stem Cells and Cell-Derived Microvesicles for Photothermal Therapy of Prostate Cancer
Abstract
Targeted delivery of nanomedicines into the tumor site and improving the intratumoral distribution remain challenging in cancer treatment. Here, we report an effective transportation system utilizing both of mesenchymal stem cells (MSCs) and their secreted microvesicles containing assembled gold nanostars (GNS) for targeted photothermal therapy of prostate cancer. The stem cells act as a cell carrier to actively load and assemble GNS into the lysosomes. Accumulation of GNS in the lysosomes facilitates the close interaction of nanoparticles, which could result in a 20 nm red-shift of surface plasmon resonance of GNS with a broad absorption in the near infrared region. Moreover, the MSCs can behave like an engineering factory to pack and release the GNS clusters into microvesicles. The secretion of GNS can be stimulated via light irradiation, providing an external trigger-assisted approach to encapsulate nanoparticles into cell derived microvesicles. In vivo studies demonstrate that GNS-loaded MSCs have an extensive intratumoral distribution, as monitored via photoacoustic imaging, and efficient antitumor effect under light exposure in a prostate-cancer subcutaneous model by intratumoral and intravenous injection. Our work presents a light-responsive transportation approach for GNS in combination of MSCs and their extracellular microvesicles and holds the promise as an effective strategy for targeted cancer therapy including prostate cancer.
Keywords: gold nanostars; mesenchymal stem cells; microvesicles; photothermal therapy; targeted transportation.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
Similar articles
-
Matrix metallopeptidase 2 targeted delivery of gold nanostars decorated with IR-780 iodide for dual-modal imaging and enhanced photothermal/photodynamic therapy.Acta Biomater. 2019 Apr 15;89:289-299. doi: 10.1016/j.actbio.2019.03.008. Epub 2019 Mar 6. Acta Biomater. 2019. PMID: 30851455
-
Synergistic Chemo-Photothermal Therapy of Breast Cancer by Mesenchymal Stem Cell-Encapsulated Yolk-Shell GNR@HPMO-PTX Nanospheres.ACS Appl Mater Interfaces. 2016 Jul 20;8(28):17927-35. doi: 10.1021/acsami.6b05677. Epub 2016 Jul 7. ACS Appl Mater Interfaces. 2016. PMID: 27356586
-
Tumor-triggered drug release from calcium carbonate-encapsulated gold nanostars for near-infrared photodynamic/photothermal combination antitumor therapy.Theranostics. 2017 Apr 10;7(6):1650-1662. doi: 10.7150/thno.17602. eCollection 2017. Theranostics. 2017. PMID: 28529642 Free PMC article.
-
Polymer decorated gold nanoparticles in nanomedicine conjugates.Adv Colloid Interface Sci. 2017 Nov;249:386-399. doi: 10.1016/j.cis.2017.01.007. Epub 2017 Feb 15. Adv Colloid Interface Sci. 2017. PMID: 28259207 Review.
-
Gold nanostars-diagnosis, bioimaging and biomedical applications.Drug Metab Rev. 2020 May;52(2):299-318. doi: 10.1080/03602532.2020.1734021. Epub 2020 Mar 9. Drug Metab Rev. 2020. PMID: 32150480 Review.
Cited by
-
Tumor-tropic Trojan horses: Using mesenchymal stem cells as cellular nanotheranostics.Theranostics. 2024 Jan 1;14(2):571-591. doi: 10.7150/thno.90187. eCollection 2024. Theranostics. 2024. PMID: 38169524 Free PMC article. Review.
-
Recent Advances in Biomimetic Nanocarrier-Based Photothermal Therapy for Cancer Treatment.Int J Mol Sci. 2023 Oct 23;24(20):15484. doi: 10.3390/ijms242015484. Int J Mol Sci. 2023. PMID: 37895165 Free PMC article. Review.
-
A phenol amine molecule from Salinivenus iranica acts as the inhibitor of cancer stem cells in breast cancer cell lines.Sci Rep. 2023 Aug 4;13(1):12669. doi: 10.1038/s41598-023-39736-9. Sci Rep. 2023. PMID: 37542193 Free PMC article.
-
Recent Advances in Cell Membrane Coated-Nanoparticles as Drug Delivery Systems for Tackling Urological Diseases.Pharmaceutics. 2023 Jul 6;15(7):1899. doi: 10.3390/pharmaceutics15071899. Pharmaceutics. 2023. PMID: 37514085 Free PMC article. Review.
-
Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches.Pharmaceutics. 2023 Jun 19;15(6):1767. doi: 10.3390/pharmaceutics15061767. Pharmaceutics. 2023. PMID: 37376215 Free PMC article. Review.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
-
- Heidenreich A, Bastian PJ, Bellmunt J. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79. - PubMed
-
- Penson DF, McLerran D, Feng Z. et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol. 2008;179(5 Suppl):S40–4. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
